Contraception
Volume 63, Issue 6 , Pages 297-302 , June 2001

Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials☆

  • PonJola Coney

      Affiliations

    • Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine, Springfield, IL, USA
    • ,
  • Ken Washenik

      Affiliations

    • Department of Dermatology, New York University Medical Center, New York, NY, USA
    • ,
  • Richard G.B. Langley

      Affiliations

    • Massachusetts General Hospital, Boston, MA, USA
    • Current Address: Dalhousie University, Halifax, Nova Scotia.
    • ,
  • John J. DiGiovanna

      Affiliations

    • Department of Dermatology, Brown University Medical School/Rhode Island Hospital, Providence, RI, USA
    • ,
  • Diane D. Harrison

      Affiliations

    • Wyeth-Ayerst Laboratories, St. Davids, PA, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-610-341-3841; fax: +1-610-995-4620

Received 2 March 2001 ,Accepted 28 March 2001.

References 

  1. Hatcher RA, Trussell J, Stewart F, Stewart GK, Kowal D, Guest F, Cates W, Policar MS. The pill: combined oral contraceptives. In: Hatcher RA, et al. Contraceptive technology, 16th rev. ed. New York: Irvington Publishers Inc., 1994. p. 223–84.
  2. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives (a randomized trial of 20 μg, and 35 μg estrogen preparations). Contraception. 2000;60:321–329
  3. Wysocki S. A survey of American women regarding the use of oral contraceptives and weight gain. (abstract) Int J Gynecol Obstet. 2000;70(Suppl 1):114
  4. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril. 1971;22:609–623
  5. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial (methodological issues and adverse event incidence). Contraception. 2000;60:81–85
  6. Boerrigter PJ, Ellman H, Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg. Clin Ther. 1999;21:118–127
  7. Bannemerschult R, Hanker JP, Wünsch C, Fox P, Albring M, Brill K. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles. Contraception. 1997;56:285–290
  8. Archer DF, Maheux R, DelConte A, O’Brien FB  North American Levonorgestrel Study Group (NALSG). Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®). Am J Obstet Gynecol. 1999;181(Suppl):S39–S44
  9. Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril. 1995;63:516–521
  10. McBride WG, Macmillan IS, Heber KR. A comparative study of adverse effects of oral contraceptives. Med J Aust. 1974;2:246–250
  11. Woutersz TB, Korba VD. Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive. Int J Fertil. 1988;33:406–410
  12. Woods ER, Grace G, Havens KK, Merola JL, Emans SJ. Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients. Am J Obstet Gynecol. 1992;166:901–907
  13. Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle (results of daily measurements). Contraception. 1998;58:345–349
  14. Ramos R, Apelo R, Osteria T, Vilar E. A comparative analysis of three different dose combinations of oral contraceptives. Contraception. 1989;39:165–177
  15. Weber-Diehl F, Unger R, Lachnit U. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. Contraception. 1992;46:19–27
  16. Litchfield RE, Grunewald KK. Oral contraceptives and fat patterning in young adult women. Hum Biol. 1988;60:793–800
  17. Carpenter S, Neinstein LS. Weight gain in adolescent and young adult oral contraceptive users. J Adolesc Health Care. 1986;7:342–344
  18. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995;52:215–220
  19. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation (a prospective evaluation of frequency and reasons). Am J Obstet Gynecol. 1998;179:577–582
  20. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives (risk indicators for poor pill taking and discontinuation). Contraception. 1995;51:283–288
  21. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med. 1995;40:355–360
  22. Sear AM, Turner MN. Factors associated with short-term oral contraceptive discontinuation. Fam Plann Perspect. 1974;6:230–233
  23. Davis A, Wysocki S. Clinician/patient interaction (communicating the benefits and risks of oral contraceptives). Contraception. 1999;59(Suppl):39S–42S
  24. Herold ES, Goodwin MS. Perceived side effects of oral contraceptives among adolescent girls. Can Med Assoc J. 1980;123:1022–1026
  25. Kaunitz AM. Contraception for the adolescent patient. Int J Fertil. 1997;42:30–38
  26. Archer DF, Maheux R, DelConte A, O’Brien FB  North American Levonorgestrel Study Group (NALSG). A new low-dose monophasic combination oral contraceptive (Alesse®) with levonorgestrel 100 μg, and ethinyl estradiol 20 μg. Contraception. 1997;55:139–144

PII: S0010-7824(01)00208-6

Contraception
Volume 63, Issue 6 , Pages 297-302 , June 2001

Article Tools

* Image Usage & Resolution